MediciNova Appoints Yoshio Ishizaka to its Board of Directors

MediciNova Appoints Yoshio Ishizaka to its Board of Directors

SAN DIEGO, April 8, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc. a
biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and
the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today
announced the appointment of Mr. Yoshio Ishizaka to its Board of Directors.

Mr. Ishizaka complements the MediciNova Board with 50 years of experience in
marketing and product development with Toyota Motor Corporation (TMC). His
international experience includes assignments in Japan, Europe and the U.S.

Mr. Ishizaka started his career at TMC after graduating with a degree in law
from the Hitotsubashi University in Japan. He served as Senior Vice President
and Chief Coordinating Officer at Toyota Motor Sales, U.S.A, Inc. (TMS) from
1986 to 1990 and was instrumental in the development of the Lexus Division. He
accepted the appointment of General Manager of TMC's Europe Division in 1990
where he built an integrated, local organization in Europe. In 1992, he was
named to TMC's Board of Directors and returned to TMS U.S.A. to serve as
President from 1996 to 1999. He returned to Japan in 1999, whereupon he was
promoted to Senior Managing Director in charge of overseas operations. In
2001, he was promoted to Executive VP in overseas operations for TMC, and in
2005, became Senior Advisor to the TMC Board.

"We are extremely pleased and fortunate to add an individual with such strong
financial and international experience in a global industry to MediciNova's
Board of Directors," said Yuichi Iwaki, M.D., Ph.D., MediciNova's President
and Chief Executive Officer. "We believe Mr. Ishizaka will be a great asset to
the Company and its stockholders."

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon
acquiring and developing novel, small-molecule therapeutics for the treatment
of diseases with unmet medical needs with a commercial focus on the U.S.
market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for
neurological disorders, MN-221 for the treatment of acute exacerbations of
asthma, and MN-001 for NASH. MN-166 is being developed in multiple
indications, largely through investigator-sponsored trials and outside
funding. MediciNova is engaged in strategic partnering and consortium funding
discussions to support further development of its programs. For more
information on MediciNova, Inc., please visit

Statements in this press release that are not historical in nature constitute
forward-looking statements within the meaning of the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, without limitation, statements regarding the Company's
ability to execute on its priorities. These forward-looking statements may be
preceded by, followed by or otherwise include the words "believes," "expects,"
"anticipates," "intends," "estimates," "projects," "can," "could," "may,"
"will," "would," or similar expressions. These forward-looking statements
involve a number of risks and uncertainties that may cause actual results or
events to differ materially from those expressed or implied by such
forward-looking statements. Factors that may cause actual results or events to
differ materially from those expressed or implied by these forward-looking
statements, include, but are not limited to, risks of obtaining future partner
or grant funding for development of MN-166, MN-221 and MN-001 and risks of
raising sufficient capital when needed to fund MediciNova's operations and
contribution to clinical development, risks and uncertainties inherent in
clinical trials, including the potential cost, expected timing and risks
associated with clinical trials designed to meet FDA guidance and the
viability of further development considering these factors, product
development and commercialization risks, the uncertainty of whether the
results of clinical trials will be predictive of results in later stages of
product development, the risk of delays or failure to obtain or maintain
regulatory approval, risks associated with the reliance on third parties to
sponsor and fund clinical trials, risks regarding intellectual property rights
in product candidates and the ability to defend and enforce such intellectual
property rights, the risk of failure of the third parties upon whom MediciNova
relies to conduct its clinical trials and manufacture its product candidates
to perform as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical trials or
significant issues regarding the adequacy of clinical trial designs or the
execution of clinical trials, and the timing of expected filings with the
regulatory authorities, MediciNova's collaborations with third parties, the
availability of funds to complete product development plans and MediciNova's
ability to obtain third party funding for programs and raise sufficient
capital when needed, and the other risks and uncertainties described in
MediciNova's filings with the Securities and Exchange Commission, including
its annual report on Form 10-K for the year ended December 31, 2013 and its
subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not
be placed on these forward-looking statements, which speak only as of the date
hereof. MediciNova disclaims any intent or obligation to revise or update
these forward-looking statements.

CONTACT: Investor Contact:
         Geoff O'Brien
         Vice President
         MediciNova, Inc.

MediciNova, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.